Recently, Fosun Pharma’s subsidiary Hunan Dongting Pharmaceutical Company Limited (“Dongting Pharma”) received the “Approval Document for Supplementary Application of Drugs” of Escitalopram Oxalate issued by the Food and Drug Administration of PRC (“CFDA”). Escitalopram Oxalate passed the consistency evaluation on generic drugs.

Escitalopram Oxalate is an antidepressants, in September 2017, Dongting Pharma applied for the consistency evaluation on generic drugs of this medicine and was proceeded by CFDA. In 2017, the revenue of it sold by Dongting Pharma in China (excluding the region of Hong Kong, Macau and Taiwan) was approximately RMB7.58million. As of April 2018, Fosun Pharma spent approximately RMB 8.8million in Research and Development regarding the consistency evaluation on generic drugs of this medicine at this stage.